Ingalls & Snyder LLC Boosts Stake in Zoetis Inc. (NYSE:ZTS)
Ingalls & Snyder LLC boosted its stake in Zoetis Inc. (NYSE:ZTS) by 7.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 12,464 shares of the company’s stock after buying an additional 880 shares during the period. Ingalls & Snyder LLC’s holdings in Zoetis were worth $778,000 as of its most recent SEC filing.
Several other hedge funds have also recently modified their holdings of ZTS. Assetmark Inc. boosted its stake in shares of Zoetis by 4.6% in the first quarter. Assetmark Inc. now owns 1,918 shares of the company’s stock valued at $102,000 after buying an additional 85 shares during the last quarter. Guardian Life Insurance Co. of America boosted its stake in shares of Zoetis by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock valued at $102,000 after buying an additional 13 shares during the last quarter. Point72 Asia Hong Kong Ltd purchased a new stake in shares of Zoetis during the first quarter valued at approximately $111,000. Advisory Services Network LLC purchased a new stake in shares of Zoetis during the first quarter valued at approximately $112,000. Finally, First Interstate Bank boosted its stake in shares of Zoetis by 3.5% in the first quarter. First Interstate Bank now owns 2,250 shares of the company’s stock valued at $120,000 after buying an additional 76 shares during the last quarter. Hedge funds and other institutional investors own 95.22% of the company’s stock.
Zoetis Inc. (NYSE:ZTS) opened at 62.12 on Monday. Zoetis Inc. has a 52 week low of $46.86 and a 52 week high of $63.85. The stock has a 50 day moving average price of $62.59 and a 200 day moving average price of $57.66. The firm has a market cap of $30.49 billion, a price-to-earnings ratio of 36.12 and a beta of 1.02.
Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 4th. The company reported $0.53 EPS for the quarter, beating the Zacks’ consensus estimate of $0.48 by $0.05. The business had revenue of $1.23 billion during the quarter, compared to the consensus estimate of $1.20 billion. Zoetis had a return on equity of 65.35% and a net margin of 17.25%. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.48 earnings per share. Equities research analysts expect that Zoetis Inc. will post $2.33 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Thursday, June 15th will be given a $0.105 dividend. This represents a $0.42 dividend on an annualized basis and a dividend yield of 0.68%. The ex-dividend date is Tuesday, June 13th. Zoetis’s dividend payout ratio is currently 24.42%.
ZTS has been the subject of several research reports. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $67.00 price target for the company in a research report on Wednesday, May 10th. Jefferies Group LLC boosted their price objective on Zoetis from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, May 9th. BMO Capital Markets reissued a “buy” rating and set a $60.00 price objective on shares of Zoetis in a research note on Thursday, May 4th. Argus reissued a “buy” rating and set a $69.00 price objective (up previously from $60.00) on shares of Zoetis in a research note on Tuesday, May 30th. Finally, CL King began coverage on Zoetis in a research note on Friday, May 26th. They set a “buy” rating and a $71.00 price objective on the stock. One analyst has rated the stock with a sell rating, four have assigned a hold rating and twelve have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $64.94.
In other news, insider Catherine A. Knupp sold 5,785 shares of Zoetis stock in a transaction on Friday, May 12th. The stock was sold at an average price of $60.16, for a total value of $348,025.60. Following the completion of the sale, the insider now owns 24,415 shares of the company’s stock, valued at $1,468,806.40. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.31% of the stock is owned by insiders.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.